Napo Pharmaceuticals
Napo Pharmaceuticals, Inc.
201 Mission Street, Suite 2375
San Francisco CA 94105
Phone: (415) 963-9938
Latest news
- FDA Approves Fulyzaq - First Anti-Diarrheal Drug for HIV/AIDS Patients
31 December 2012 - FDA Continues Review of Crofelemer New Drug Application beyond PDUFA Goal Date of September 5, 2012
5 September 2012 - Napo Comments on FDA Announcing Extension of Crofelemer NDA Priority Review
3 May 2012 - Salix Pharmaceuticals Announces Extension of Crofelemer NDA Priority Review
30 April 2012 - Salix Pharmaceuticals Announces FDA Granting of Priority Review Designation for the Crofelemer NDA for Treatment of Diarrhea in Patients with HIV/AIDS on Anti-Retroviral Therapy
7 February 2012 - Salix Pharmaceuticals Announces NDA Submission for Crofelemer for the Treatment of HIV-Associated Diarrhea
14 December 2011
Drugs Associated with Napo Pharmaceuticals, Inc.
Napo Pharmaceuticals, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Mytesi
Generic name: crofelemer Drug class: antidiarrheals |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
